Background and aims-Circulating soluble urokinase plasminogen activator receptor (suPAR) is a marker of immune activation associated with atherosclerosis. Whether suPAR levels are associated with prevalent peripheral arterial disease (PAD) and its adverse outcomes remains unknown and is the aim of the study.
Introduction
Atherosclerosis is a systemic disease that can involve coronary, cerebrovascular, aortic, renal, upper and lower extremity arteries [1, 2] Although widely prevalent, peripheral artery disease (PAD) remains underdiagnosed and is associated with excessive morbidity and mortality [3] . Despite sharing common risk factors with coronary artery disease (CAD) including hypertension, advanced age, diabetes, hyperlipidemia and smoking, only 20-30% of patients with CAD develop concomitant significant PAD. In addition, endothelial dysfunction, reduced regenerative capacity, inflammation and immune dysregulation also play a fundamental role in the development and progression of PAD [1, 2, [4] [5] [6] . However, none of the markers reflecting these processes have been translated into clinical practice either for screening, risk stratification, or to monitor therapeutic response in patients with PAD.
Recently, we and others have shown that higher levels of soluble urokinase plasminogen activator receptor (suPAR), a circulating marker of inflammation, thromobogenesis, and immune regulation, are associated with hypertension, diabetes, CAD, stroke, and chronic kidney disease [7] [8] [9] [10] . SuPAR is produced by cleavage of membrane-bound urokinase-type plasminogen activator receptor, which is a membrane linked G-protein expressed on numerous inflammatory cells including monocytes, activated T-lymphocytes and macrophages as well as fibroblasts and endothelial cells. Both the circulating and membrane-bound forms are directly involved in the regulation of cell adhesion and migration through binding of integrins. The soluble form has direct chemotactic properties that may facilitate recruitment of inflammatory cells such as neutrophils and monocytes and the mobilization of hematopoietic stem cells [11] [12] [13] . Finally, SuPAR is associated with increased inflammatory activity in atherosclerotic plaques [10] .
The relationship between circulating suPAR levels and PAD and its related outcomes has not been systematically studied to date. Whether suPAR levels predict presence of PAD and whether its' levels are a measure of long-term incident risk remains unknown. The aim of this study is to examine the association between plasma suPAR levels and the presence of PAD and adverse cardiovascular and PAD-related events.
Materials and methods

Study design and population
We measured suPAR levels in 5810 adults ≥18 years from the Emory Cardiovascular Biobank, a prospective cohort of patients undergoing left heart catheterization for suspected or confirmed CAD at Emory Healthcare sites in Atlanta, GA, between 2003 and 2015. Subjects with congenital heart disease, heart transplantation, severe anemia, active inflammatory diseases, and cancer were excluded. Participants were interviewed to collect demographic characteristics, medical history, medication use, and behavioral habits as previously described [14] . Medical records and ICD-9 diagnostic codes were reviewed to confirm self-reported medical history. Angiograms performed at enrollment were reviewed, and obstructive CAD was defined as the presence of ≥50% stenosis in at least one coronary artery. The study was approved by the institutional review board at Emory University (Atlanta, GA). All subjects provided written informed consent at the time of enrollment.
Defining peripheral arterial disease
We extensively reviewed patients' self-reported and physician-documented medical history and imaging reports to identify the presence of PAD as previously described [6] . PAD was defined as a history of symptomatic or asymptomatic non-coronary atherosclerotic disease in at least one of the following arteries: carotid, thoracic or abdominal aorta, subclavian, brachial, iliac, femoral, or popliteal arteries. No routine testing was performed to screen for asymptomatic PAD. PAD of the lower extremities was diagnosed when at least one of the following were present: documented ankle-brachial index <0.90; lower limb revascularization; atherosclerotic plaques or stenosis on imaging ≥50% (computed tomography, ultrasound, or fluoroscopy) in the iliac, femoral, or popliteal arteries; and history of amputation for critical limb ischemia. All subjects with extremities PAD were symptomatic. PAD of the carotid artery was diagnosed if there was ≥20% stenosis in any carotid artery. Subgroup analysis was done to compare those with mild vs. severe carotid disease using higher cutoffs of 25% and 50%. Aortic disease was diagnosed when there was a history abdominal (greater than 4 cm) or thoracic (ascending greater than 4 cm or descending diameter larger than 3 cm) aneurysms after (excluding subjects with aortic root aneurysm associated with bicuspid aortic valves) or evidence of moderate-to-severe (frequent, large plaques) atherosclerotic plaques of the aorta or renal arteries on computed tomography imaging.
Sample collection and measurement of suPAR
Fasting arterial blood samples were collected at the time of catheterization and stored at −80 °C. Plasma levels of suPAR were measured (suPARnostic kit; ViroGates, Copenhagen, Denmark) with a lower detection limit of 100 pg/mL and intra-and inter-assay variation of 2.75% and 9.17%, respectively [8] . Serum high-sensitivity C-reactive protein (CRP) levels were determined in 3452 patients (59.4%) using a particle-enhanced immunoturbidimetry assay (FirstMark, a division of GenWay Biotech) that has a lower limit of detection of 0.03 mg per liter [15] .
Follow-up and outcomes
We conducted follow-up as previously described to identify prespecified incident adverse cardiovascular outcomes including death, cardiovascular death and PAD-related events. In brief, follow-up and adjudication were conducted by personnel blinded to the SuPAR data by phone, electronic medical record review, as well as and social security death index and state records. PAD-related events such as peripheral revascularization, amputation and stroke were identified using standard current procedural terminology codes for vascular procedures, chart review and followup questionnaire [6] .
Statistical analysis
We reported subject characteristics as descriptive statistics with means, standard deviations, frequency counts, percentages, medians, and interquartile ranges. Differences between groups were assessed using the t-test for continuous variables, and chi-square for categorical variables. Two-tailed P-value ≤0.05 were considered statistically significant. For nonnormally distributed variables such as suPAR and CRP levels, the Mann-Whitney U test was used to compare groups in unadjusted analyses. For multivariable analyses, suPAR levels were examined both as a categorical variable stratified by tertiles, and as a continuous variable after log-transforming, and reported as "per 25% increase in suPAR". Covariates incorporated in multivariable analyses included age, gender, race, body mass index (BMI), smoking history, hypertension, diabetes, estimated glomerular filtration rate (eGFR calculated using the CKD-EPI equation), presence of obstructive CAD, statin use, antiplatelet therapy, angiotensin pathway antagonist use, beta-blocker therapy, suPAR and hs-CRP levels. Logistic regression was performed to investigate independent predictors of prevalent PAD. Regression coefficients are presented as point estimates with 95% confidence intervals. We examined the collinearity among all the continuous variables using Pearson and Spearman correlation when appropriate. We found that the highest two correlations observed were 0.4 and 0.5. We further examined the tolerance values and none of them were <0.1. We also did not find a large standard errors for any of the estimates. The Kaplan-Meier curves as well as Cox proportional-hazards regression model were used to examine the association between suPAR and all-cause death, cardiovascular death, and PADrelated outcomes. Analysis was conducted using available data (9% with missing data) under the assumption of missing completely at random. Analyses were performed using IBM SPSS Statistics Version 22, (Armonk, NY, USA) and R 3.2.2 (R Core Team, Vienna, Austria). Lastly, we examined the incremental value of adding suPAR levels to a clinical model for predicting death. The c-statistic, continuous net reclassification improvement (NRI), and integrated discrimination improvement (IDI) were calculated to evaluate the improvement in predictive ability of the models with and without SuPAR using the R packages survC1 and survIDINRI. 
Results
Characteristics of the 5810 patients enrolled are shown in Table 1 . The mean age of the cohort was 63.5 (±12.2) years, 63% male and 77% had significant CAD (>50% luminal stenosis).
SuPAR and PAD characteristics
Baseline characteristics according to CAD and PAD diagnoses are shown in Table 1 In multivariable analyses, independent predictors for the presence of PAD included age, smoking, BMI, diabetes, hypertension, eGFR, heart failure, obstructive CAD and plasma suPAR level (Table 2) . SuPAR in the highest compared to lowest tertile had an odds ratio (OR) of 2.0 (95% CI 1.6-2.5) p < 0.001 for presence of PAD. Similarly, using suPAR as a continuous variable, for each 25% increase in suPAR level, the OR of prevalent PAD increased by 13% (95% CI 1.08-1.18) p < 0.001 (Table 2 ).
In the 3452 (59.4%) patients with hs-CRP levels, there was no association between hs-CRP levels and prevalent PAD. Moreover, suPAR remained an independent predictor of PAD after adjustment for the hs-CRP level.
SuPAR and cardiovascular outcomes in PAD
In 968 patients with PAD, there were 245 (25.3%) deaths from all causes, 156 (16.1%) deaths from cardiovascular causes, and 79 (8.2%) incident myocardial infarcts over a median follow-up period of 3.4 (IQR 1.6-6.6) years. In unadjusted analyses, a 25% increase in suPAR level was associated with increased risk of all-cause death [HR = 1.4 (95% CI 1. Table 3 . We obtained similar results using a model adjusted for variables that correlated in univariate analysis with the outcome of death (included black, age, BMI, heart failure, diabetes, statin use, and eGFR). These results remained significant even after adjusting for hs-CRP levels (n = 524).
Mortality was higher in subjects with multisite PAD (34.6%) followed by extremities PAD (32.1%) followed by aortic PAD (28.2%) followed by carotid PAD (26.0%) although this didn't reach statistical significance (Log Rank p = 0.32). Death rate was similar in those with mild vs. severe carotid stenosis using 50% as cutoff (25% vs 28%, p = 0.4). Subjects with symptomatic PAD had increased risk of death compared to asymptomatic subjects with HR 1.29 (95% CI 1.03-1.63); p = 0.04 but became not significant in fully adjusted model (p = 0.096).
In patients with and without PAD, there were 347 (6.6%) PAD-related events over the follow-up period. In an adjusted Cox regression model, independent predictors of PADrelated events were smoking, lower BMI, hypertension, CAD, HF, clopidogrel use, and the suPAR level [HR = 1.8, 95% CI (1.4-2.5) p < 0.001] highest vs. lowest tertile. Similarly, each 25% increase in the suPAR level was associated with a 17% increase in the risk of PAD-related events [HR = 1.17 95% CI (1.09-1.24) p < 0.001], Table 4 and Fig. 3 . 
Discussion
This is the first study to demonstrate that elevated plasma SuPAR levels are associated with prevalent PAD and its adverse outcomes. SuPAR levels are higher in subjects with PAD compared to those with only CAD and are highest in those with both PAD and CAD. Furthermore, patients with more diffuse and multi-site PAD have the highest levels of SuPAR. Most importantly, a higher SuPAR level was associated with an increase in all-cause and cardiovascular mortality, as well as PAD-related events and improved risk discrimination metrics when added to a model with traditional risk factors.
We and others have previously reported that elevated suPAR levels are associated with cardiovascular risk factors, subclinical and clinical cardiovascular disease including CAD, adverse cardiovascular outcomes and progression of chronic kidney disease [7, [16] [17] [18] 8, 9, [19] [20] [21] [22] [23] [24] [25] [26] . Higher plasma and intra-plaque suPAR levels were noted to be associated with symptomatic carotid stenosis and vulnerable plaques [10] . Another study showed that uPAR expression in the intima of atherosclerotic lesions was progressively higher with increasing severity of atherosclerosis in human coronary and aortic vessel segements [27] . Our current investigation extends these findings to subjects with PAD. We also found a graded relationship between the extent of peripheral atherosclerosis, estimated as the number of diseased vascular beds and suPAR levels, suggesting that suPAR levels reflect the underlying atherosclerotic burden whether it involves the coronary or peripheral circulations.
Atherosclerosis is a complex process that is initiated by injury to the vascular endothelium, formation of plaque and its subsequent expansion and often sudden progression to acute coronary syndromes [1] . Endothelial injury promotes activation and migration of inflammatory cells into the sub-endothelial space with differentiation into macrophages [1, 28] , processes that are modulated by uPAR and suPAR. Experimental studies have demonstrated that uPAR and its soluble form, suPAR play a critical role in cell adhesion and migration, intercellular signaling, matrix degradation and proliferation [18, [28] [29] [30] . suPAR can downregulate immune defenses by inhibiting neutrophil efferocytosis (clearance of apoptotic cells) and membrane-bound uPAR facilitates phagocytosis.
The role of inflammatory biomarkers in PAD has been previously studied. For example, interleukin-6, tumor necrosis factor α, intercellular adhesion molecules and CRP levels are higher in patients with PAD [31-33] but their role on predicting PAD-related events remains unclear as these follow-up studies are small and unvalidated [34] . In almost 1000 patients extensively phenotyped for PAD, we demonstrate the value of suPAR in predicting incident adverse events independent of hs-CRP levels, suggesting that suPAR reflects more than an activated inflammatory state.
Our study has important strengths. These include a large cohort size with detailed phenotyping of PAD, long term follow-up with a large number of cardiovascular and PADrelated events, and exploration of the interaction with inflammation assessed by hs-CRP. It is possible that some patients with asymptomatic PAD were undiagnosed because of the lack of systematic screening that remains a limitation of our cohort.
In conclusion, this is the first and largest comprehensive study to demonstrate that levels of suPAR are higher in patients with PAD, particularly in those with extensive atherosclerosis and are predictive of long term cardiovascular and PAD-related outcomes. Whether SuPAR is a useful biomarker to screen for, risk stratify, or to monitor therapeutic response to PAD treatment requires further investigation.
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